A deeper shade of green
Inspiring sustainable drug manufacturing
Frank Roschangar (Boehringer Ingelheim Pharmaceuticals, Inc.)
Juan Colberg (Pfizer Inc.)
Peter J. Dunn (Pfizer Limited, UK)
Fabrice Gallou (Novartis Pharma)
John D. Hayler (GlaxoSmithKline)
Stefan G. Koenig (Genentech Inc.)
Michael E. Kopach (Eli Lilly and Company)
David K. Leahy (Bristol-Myers Squibb)
Ingrid Mergelsberg (Merck & Co., Inc.)
John L. Tucker (Process Development Amgen)
R.A. Sheldon (University of Witwatersrand, TU Delft - BT/Biocatalysis)
Chris H. Senanayake (Boehringer Ingelheim Pharmaceuticals, Inc.)
More Info
expand_more
Abstract
Green and sustainable drug manufacturing go hand in hand with forward-looking visions seeking to balance the long-term sustainability of business, society, and the environment. However, a lack of harmonization among available metrics has inhibited opportunities for green chemistry in industry. Moreover, inconsistent starting points for analysis and neglected complexities for diverse manufacturing processes have made developing objective goals a challenge. Herein we put forward a practical strategy to overcome these barriers using data from in-depth analysis of 46 drug manufacturing processes from nine large pharmaceutical firms, and propose the Green Aspiration Level as metric of choice to enable the critically needed consistency in smart green manufacturing goals. In addition, we quantify the importance of green chemistry in the often overlooked, yet enormously impactful, outsourced portion of the supply chain, and introduce the Green Scorecard as a value added sustainability communication tool.
No files available
Metadata only record. There are no files for this record.